Any current/future new fundraising through debt or equity?

No explicit mention of any current or upcoming fundraising through debt or equity in the transcript. Capital expenditure during the quarter was Rs.116 crore, primarily funded through internal accruals. The company’s net debt as of June 30, 2024, was Rs.677 crore with a net debt-to-equity ratio of 1.5x based on trailing 12-month EBITDA. No indication from management about plans for incremental debt or equity raising. Focus appears to be on internal funding for expansion and ongoing initiatives.

Any current/future capex/capital investment/strategic investment?

Commissioned an agrochemical plant in January 2024 capable of producing both intermediates and active ingredients; currently under evaluation. Plans to undertake modifications and incremental CAPEX in the agrochemical plant to meet demand. Significant investment has already been made in the new agrochemical plant. Expansion plans for fine chemicals with multipurpose plants at Gajraula and Bharuch facilities expected to serve growth for the next five years. Ongoing CAPEX of Rs. 116 crore in Q1 FY25 funded primarily through internal accruals. Multiple initiatives under "Pinnacle 345" growth road

Future growth expectations in sales/revenue/volumes?

Jubilant Ingrevia aims to grow revenue 3x from FY24 to FY29, targeting Rs. 12,000 to Rs. 13,000 crore+ revenue. Specialty Chemicals business expected to grow steadily with 23%-25% EBITDA margin aspirational target. CDMO business (Pharma and Agro) to grow at least 20%-25% annually, with several advanced-stage opportunities to convert. Agrochemical demand and volumes expected to recover gradually with easing inventory destocking; growth moderated but steady. Nutrition business volumes increased ~14%-15% QoQ, with future improvement hinging on new food/cosmetic grade products launching in

Future growth expectations in earnings/operating earnings/profits/EPS?

Jubilant Ingrevia aspires to grow revenue from a steady state of ~Rs. 4,500 crore to Rs. 12,000-13,000 crore in five years (Pinnacle 345 vision). Target EBITDA margin is 20%+ at the overall company level, with Specialty Chemicals expected to achieve 23%-25% EBITDA margins. Nutrition segment margins are anticipated to improve to 17%-18%+ with the addition of specialty products and new plants. The acetyl business is expected to sustain EBITDA margins around 10%-12%. Specialty Chemicals business aims to sustain 20%+ EBITDA and potentially reach closer to 24%-25% as new products and CDMO o

Current/ Expected Orderbook/ Pending Orders?

The company is in the advanced stages of discussions with an agrochemical customer for a contract; the first objective is to sign the contract before finalizing servicing details. The CDMO business is witnessing strong traction with new orders delivered during the quarter. There are multiple projects in advanced discussions across Pharma, Agro, and Semiconductor sectors. The Semiconductor-related CDMO opportunities have grown from 4-5 leads to 10-12 real leads, with samples already supplied to some customers. Growth aspiration for CDMO business is steady at 20%-25% CAGR, with a potenti

IN US

Sale is live|00:00:00left today

Jubilant Ingrevia LtdQ2 FY24Chemicals & Petrochemicals

Jubilant Ingrevia Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹632P/E: 42.4Market Cap: ₹11.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Jubilant Ingrevia aims to grow revenue 3x from FY24 to FY29, targeting Rs. 12,000 to Rs. 13,000 crore+ revenue.
→Specialty Chemicals business expected to grow steadily with 23%-25% EBITDA margin aspirational target.
→CDMO business (Pharma and Agro) to grow at least 20%-25% annually, with several advanced-stage opportunities to convert.
→Agrochemical demand and volumes expected to recover gradually with easing inventory destocking; growth moderated but steady.
→Nutrition business volumes increased ~14%-15% QoQ, with future improvement hinging on new food/cosmetic grade products launching in Q3 FY25.
→New product lines (diketene, food-grade choline bitartrate) showing strong traction and contributing to volume growth.
→Overall specialty segments reported stable or increasing volumes seasonally, with expectations of volume growth in FY25 compared to FY24.
→Continued focus on customer centricity and ramping up new plants to sustain growth momentum.

Margin guidance

Category 1

→Jubilant Ingrevia aspires to grow revenue from a steady state of ~Rs. 4,500 crore to Rs. 12,000-13,000 crore in five years (Pinnacle 345 vision).
→Target EBITDA margin is 20%+ at the overall company level, with Specialty Chemicals expected to achieve 23%-25% EBITDA margins.
→Nutrition segment margins are anticipated to improve to 17%-18%+ with the addition of specialty products and new plants.
→The acetyl business is expected to sustain EBITDA margins around 10%-12%.
→Specialty Chemicals business aims to sustain 20%+ EBITDA and potentially reach closer to 24%-25% as new products and CDMO opportunities scale up.
→CDMO business is expected to grow at 20%-25% yearly, contributing significantly to profits.
→Cost-saving initiatives are estimated to bring Rs. 120-140 crore annualized savings, enhancing profitability.
→Overall, the company targets a 3x revenue and 4x EBITDA growth in five years from FY24 base, delivering strong earnings and EPS growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any current or upcoming fundraising through debt or equity in the transcript.
→Capital expenditure during the quarter was Rs.116 crore, primarily funded through internal accruals.
→The company’s net debt as of June 30, 2024, was Rs.677 crore with a net debt-to-equity ratio of 1.5x based on trailing 12-month EBITDA.
→No indication from management about plans for incremental debt or equity raising.
→Focus appears to be on internal funding for expansion and ongoing initiatives.

Order book

Yes

→The company is in the advanced stages of discussions with an agrochemical customer for a contract; the first objective is to sign the contract before finalizing servicing details.
→The CDMO business is witnessing strong traction with new orders delivered during the quarter.
→There are multiple projects in advanced discussions across Pharma, Agro, and Semiconductor sectors.
→The Semiconductor-related CDMO opportunities have grown from 4-5 leads to 10-12 real leads, with samples already supplied to some customers.
→Growth aspiration for CDMO business is steady at 20%-25% CAGR, with a potential jump based on lumpier agrochemical projects.
→Overall, the company is building a robust CDMO opportunity pipeline for the coming years, although timing of revenue realization is uncertain due to the nature of the business.
→Expansion plans for the next 5 years can be accommodated within the existing Gajraula and Bharuch facilities.

Capex plans

Yes

→Commissioned an agrochemical plant in January 2024 capable of producing both intermediates and active ingredients; currently under evaluation.
→Plans to undertake modifications and incremental CAPEX in the agrochemical plant to meet demand.
→Significant investment has already been made in the new agrochemical plant.
→Expansion plans for fine chemicals with multipurpose plants at Gajraula and Bharuch facilities expected to serve growth for the next five years.
→Ongoing CAPEX of Rs. 116 crore in Q1 FY25 funded primarily through internal accruals.
→Multiple initiatives under "Pinnacle 345" growth roadmap, including investments in high potential product categories and sustainability efforts such as sourcing renewable energy.
→CDMO business expected to grow with steady investments, targeting 25%-30% year-on-year growth; includes pharma, agro, and semiconductor opportunities.

How does Jubilant Ingrevia Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Jubilant Ingrevia Ltd

Rev 2Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Jubilant Ingrevia Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio